Numerous reports—about levels of Ang1 and Ang2 increasing in diabetic retinopathy [366,367], AMD [368], ROP [369], and upregulation of vascular endothelial-protein tyrosine phosphatase (VE-PTP) in retinal neovascularization [370]—indicate that this pathway is a promising compensational therapeutical target for vascular ocular diseases, in concert with anti-VEGF therapy [371]. The gene discussed is PTPRB; the disease is retinopathy of prematurity.